These findings suggest that glucagon-like peptide-1 receptor agonist monotherapy may alter some nicotine outcomes in people who smoke, irrespective of cessation treatment.
Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial